Hundreds of prescriptions for GLP-1 medicines were issued for under-18s in England over two recent periods, according to newly reported figures. Some of the prescriptions were for children younger than 12.
The numbers count prescriptions, not individual patients. They do not establish that hundreds of different children received the medicines, or that every prescription was for weight management.
The reported figures, obtained through freedom of information requests and made public on 14 November, cover prescriptions written in England and dispensed in community settings across the UK. They show 419 prescriptions for under-18s in the 2025–26 financial year, including ten for children under 12.
A further 341 prescriptions for under-18s were recorded in the separate period from April to July 2026. The periods are different lengths, and a patient may have more than one prescription. The totals therefore cannot be read as numbers of children or directly compared as if they covered the same amount of time.
What the figures leave out
The community figures do not include private prescriptions, or prescriptions both issued and dispensed in hospitals or prisons. They are consequently not a complete count of all use of these medicines by children. Equally, they do not reveal how many children obtained them outside the recorded settings.
The reported totals do not identify each patient’s diagnosis, the clinical reason for treatment or the care arrangement behind a prescription. They do not show that any individual child received a medicine inappropriately. Those questions require more information than the published counts provide.
GLP-1 medicines mimic a hormone involved in appetite and blood sugar regulation. Some are used to treat type 2 diabetes, while others are authorised for weight management; the permitted uses and age limits differ between products. Referring to every prescription as a weight-loss jab would therefore give a misleading impression. Some medicines in this group are also available as tablets rather than injections.
Care for children with obesity
Specialist services for children with complications from severe obesity bring together different professionals to assess physical health, mental health and family circumstances. A care plan may include dietary support, behavioural coaching and help with mental health, as well as treatment of related conditions. Medication is not the only form of care.
International guidance on childhood obesity recommends structured support for diet, physical activity and behaviour. It does not recommend drug treatment for obesity in children under ten. For those aged ten to 19, it says approved medicines may be considered when a supervised programme involving several approaches has not achieved the desired results.
That guidance concerns treatment for obesity; it does not establish why a particular child was prescribed a GLP-1 medicine. It is also distinct from the product-specific licensing and prescribing rules that apply in the UK.
Children’s treatment needs individual assessment and follow-up. Growth, nutrition, wellbeing and possible side effects are among the matters clinicians may need to monitor. Nausea, vomiting and diarrhoea are common side effects of GLP-1 medicines and can sometimes lead to dehydration. Anyone concerned about a prescribed medicine should speak to the clinician responsible for the child’s care rather than changing treatment without advice.
The wider picture
Separate school measurements from the 2025–26 academic year give context to the discussion. In England, 10.7 per cent of measured reception pupils aged four and five were classified as living with obesity, compared with 22.8 per cent of measured year 6 pupils aged ten and 11.
There were differences between areas. Among measured year 6 pupils, obesity prevalence was 30.3 per cent in the most deprived areas and 13.9 per cent in the least deprived. These are population measurements, not a count of children eligible for medication or evidence that any particular child needs it.
For families with concerns about a child’s weight or growth, a GP or school nurse can offer advice and discuss suitable support. Decisions about medicines depend on the individual child, the condition being treated and the benefits and risks of the particular product.